The first peptide to attract attention was GIP, soon followed by GLP-1 because of its more suitable features as a pharmacological agent for improvement of glucose control and body-weight reduction in people with type 2 diabetes [4]. This evidence concerns the gene GCG and type 2 diabetes mellitus.